Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”
Some disability advocates take issue with the “normalization” goals of the medical model of rehabilitation, but expressions of that position can be dismissive of rehabilitationists’ efforts to remediate oppressive functional deficits.
AMA J Ethics. 2015;17(6):562-567. doi:
10.1001/journalofethics.2015.17.6.msoc1-1506.
Jennifer T. McIntosh, PhD, RN, CNE, PMH-BC, NEA-BC and Mona Shattell, PhD, RN
This commentary examines prevention policies that overly rely on liberty restrictions imposed by designs of inpatient psychiatric units’ structures and spaces.
AMA J Ethics. 2024;26(3):E199-204. doi:
10.1001/amajethics.2024.199.
Therapeutic security in inpatient psychiatric settings requires careful planning and implementation if it is to support both patients’ safety and dignity.
AMA J Ethics. 2024;26(3):E205-211. doi:
10.1001/amajethics.2024.205.